GSK Gets FDA Approval For Asthma Drug Arnuity Ellipta

(RTTNews) - GlaxoSmithKline plc (GSK, GSK.L) said Wednesday that the FDA has approved Arnuity Ellipta, a once-daily inhaled corticosteroid medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older.

Arnuity is not indicated for relief of acute bronchospasm.

The approved doses are Arnuity Ellipta 100mcg and 200mcg. Arnuity Ellipta is administered once daily via the dry powder inhaler called Ellipta, which is also used across a range of other approved respiratory medicines in the GSK portfolio.

According to GlaxoSmithKline, the efficacy and safety of Arnuity Ellipta have been evaluated in more than 3,600 patients with asthma.